1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow CPI-444: new trials by email Literature Review of CPI-444 trials Research Report on CPI-444
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma Ciforadenant, daratumumab - Multiple Myeloma | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 7 | 2020-02-20 | 2022-03-11 |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) Atezolizumab, Cobimetinib, RO6958688 - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 314 | 2017-12-27 | 2026-05-12 |
Carcinoma, Non-Small-Cell Lung (1) · Multiple Myeloma (1)
Corvus Pharmaceuticals, Inc. (1) · Hoffmann-La Roche (1)
United States (2) · Australia (1) · France (1) · Israel (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Deborah Strahs (1)
2017 (1)